Compare Gilead Sciences, Inc. (GILD) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X Defense Tech ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Global X Defense Tech ETF trades at $59.61 (market cap $6.38B). The key difference: Gilead Sciences, Inc. is far larger — about 28.5× Global X Defense Tech ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Global X Defense Tech ETF for 44 Days on average.
| GILD | SHLD | |
|---|---|---|
Market Cap | $182.09B | $6.38B |
Volume | 4,960,247 | 1,280,546 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $78.02 |
52-Week Low | $116.74 | $58.20 |
Typical Hold Time | 111 Days | 44 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
SHLD (Global X Defense Tech ETF) trades at $58.74, down 2.2% on the day amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though oversold RSI readings at 10.99 (6-day) and 15.12 (12-day) suggest potential for near-term bounce. Recent institutional filings show increased buying interest from firms like Focus Financial Network (+55.4% stake) and Balefire LLC ($1.12M new position) in Q2 2026, indicating professional confidence in defense tech exposure.
The defense technology sector benefits from geopolitical tensions and rising global military budgets, with EU allies planning significant rearmament spending. However, the ETF's concentrated focus on emerging tech carries execution risks versus broader aerospace peers. Current technical weakness contrasts with fundamental tailwinds, creating a divergence that may resolve with either sector momentum recovery or continued ETF-specific pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
